FDA Drug Recalls

Recalls / Class II

Class IID-1343-2019

Product

Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection, 250 mL EXCEL Container bag, Rx only, B. Braun Medical Inc., Bethlehem, PA 18018-3524 USA, API from SPAIN, NDC 0264-9587-20.

Brand name
Heparin Sodium In Dextrose
Generic name
Heparin Sodium And Dextrose
Active ingredients
Dextrose Monohydrate, Heparin Sodium
Route
Intravenous
NDCs
0264-9567, 0264-9577, 0264-9587
FDA application
NDA019952
Affected lot / code info
Lot #: J7B259, Exp 31 Aug 2019

Why it was recalled

Subpotent Drug: low out-of-specification results were identified for the drug anti-factor IIa potency which is intended to ensure that the potency of heparin is within the USP specifications.

Recalling firm

Firm
B. Braun Medical Inc
Manufacturer
B. Braun Medical Inc.
Notification channel
E-Mail
Type
Voluntary: Firm initiated
Address
2525 Mcgaw Ave, N/A, Irvine, California 92614-5841

Distribution

Quantity
40,176 bags
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2019-06-13
FDA classified
2019-06-13
Posted by FDA
2019-06-19
Terminated
2022-07-15
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1343-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Heparin Sodium In Dextrose · FDA Drug Recalls